日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose Administration

MD-4251:一种首创的口服MDM2降解剂,单次给药即可诱导肿瘤完全消退

Acharyya, Ranjan Kumar; Huang, Liyue; Aguilar, Angelo; Hu, Biao; Bai, Longchuan; Metwally, Hoda; McEachern, Donna; Jiang, Wei; Wang, Yu; Li, Qiuxia; Wen, Bo; Sun, Duxin; Wang, Shaomeng

Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia

MD-265 的发现:一种强效的 MDM2 降解剂,可实现肿瘤完全消退并提高白血病小鼠的长期生存率

Aguilar, Angelo; Yang, Jiuling; Li, Yangbing; McEachern, Donna; Huang, Liyue; Razzouk, Stevenchoukry; Wang, Shaomeng

Strategies for the drug discovery and development of taxane anticancer therapeutics

紫杉烷类抗癌药物的发现和开发策略

Wang, Changwei; Aguilar, Angelo; Ojima, Iwao

Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong In Vivo Antitumor Activity.

发现 M-808 是一种高效的共价小分子抑制剂,可抑制 Menin-MLL 相互作用,并具有很强的体内抗肿瘤活性

Xu Shilin, Aguilar Angelo, Huang Liyue, Xu Tianfeng, Zheng Ke, McEachern Donna, Przybranowski Sally, Foster Caroline, Zawacki Kaitlin, Liu Zhaomin, Chinnaswamy Krishnapriya, Stuckey Jeanne, Wang Shaomeng

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

发现 MD-224 是一种首创的、高效且具有靶向嵌合鼠双微体 2 降解作用的蛋白水解剂,能够实现完全且持久的肿瘤消退。

Li, Yangbing; Yang, Jiuling; Aguilar, Angelo; McEachern, Donna; Przybranowski, Sally; Liu, Liu; Yang, Chao-Yie; Wang, Mi; Han, Xin; Wang, Shaomeng

Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.

基于结构的 CF53 发现是一种强效且口服生物利用度高的溴结构域和末端外 (BET) 溴结构域抑制剂

Zhao Yujun, Zhou Bing, Bai Longchuan, Liu Liu, Yang Chao-Yie, Meagher Jennifer L, Stuckey Jeanne A, McEachern Donna, Przybranowski Sally, Wang Mi, Ran Xu, Aguilar Angelo, Hu Yang, Kampf Jeff W, Li Xiaoqin, Zhao Ting, Li Siwei, Wen Bo, Sun Duxin, Wang Shaomeng

Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges

靶向MDM2-p53蛋白-蛋白相互作用的新型癌症疗法:进展与挑战

Wang, Shaomeng; Zhao, Yujun; Aguilar, Angelo; Bernard, Denzil; Yang, Chao-Yie

Chemical synthesis of tetracyclic terpenes and evaluation of antagonistic activity on endothelin-A receptors and voltage-gated calcium channels

四环萜类化合物的化学合成及其对内皮素A受体和电压门控钙通道的拮抗活性评价

Lu, Jianyu; Aguilar, Angelo; Zou, Bende; Bao, Weier; Koldas, Serkan; Shi, Aibin; Desper, John; Wangemann, Philine; Xie, Xinmin Simon; Hua, Duy H

Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.

基于结构的强效 Bcl-2/Bcl-xL 抑制剂设计及其在体内强大的抗肿瘤活性

Zhou Haibin, Aguilar Angelo, Chen Jianfang, Bai Longchuan, Liu Liu, Meagher Jennifer L, Yang Chao-Yie, McEachern Donna, Cong Xin, Stuckey Jeanne A, Wang Shaomeng

Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold.

基于新型支架设计具有亚纳摩尔级结合亲和力的 Bcl-2 和 Bcl-xL 抑制剂

Zhou Haibin, Chen Jianfang, Meagher Jennifer L, Yang Chao-Yie, Aguilar Angelo, Liu Liu, Bai Longchuan, Cong Xin, Cai Qian, Fang Xueliang, Stuckey Jeanne A, Wang Shaomeng